Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT – Get Free Report) was the target of a significant drop in short interest during the month of August. As of August 31st, there was short interest totaling 173,858 shares, a drop of 52.0% from the August 15th total of 362,103 shares. Currently, 0.4% of the shares of the company are sold short. Based on an average daily trading volume, of 247,213 shares, the short-interest ratio is currently 0.7 days.
Institutional Trading of Zhengye Biotechnology
Large investors have recently made changes to their positions in the business. Geode Capital Management LLC purchased a new position in shares of Zhengye Biotechnology during the second quarter worth $174,000. Invesco Ltd. acquired a new stake in Zhengye Biotechnology during the 2nd quarter worth about $220,000. Jane Street Group LLC acquired a new stake in Zhengye Biotechnology during the 2nd quarter worth about $1,158,000. WINTON GROUP Ltd purchased a new position in shares of Zhengye Biotechnology during the 3rd quarter valued at about $56,000. Finally, Citadel Advisors LLC purchased a new position in shares of Zhengye Biotechnology during the 3rd quarter valued at about $31,000.
Zhengye Biotechnology Stock Performance
Shares of NASDAQ ZYBT opened at $1.55 on Monday. Zhengye Biotechnology has a 52 week low of $0.62 and a 52 week high of $11.45. The business’s 50 day moving average price is $1.62 and its 200 day moving average price is $1.13. The company has a current ratio of 1.14, a quick ratio of 0.82 and a debt-to-equity ratio of 0.03.
Wall Street Analysts Forecast Growth
View Our Latest Analysis on Zhengye Biotechnology
Zhengye Biotechnology Company Profile
Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.
Featured Stories
- Five stocks we like better than Zhengye Biotechnology
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Zhengye Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zhengye Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
